Due diligence on generic therapeutic Challenge A private investment firm was seeking an independent reality-check on a potential investment in a pharmaceutical company that had recently in-licensed a generic therapeutic asset. The firm asked Alacrita to evaluate the upside case for the pharmaceutical company based on the newly in-licensed asset, as well as a core business evaluation of the pharmaceutical company to understand the downside risk and possible significant opportunities apart from the newly in- licensed asset. Solution Alacrita performed a due diligence on the pharmaceutical company and the generic asset. The analysis on the pharmaceutical company included a review of the company’s current strategy, business, and pipeline. Analysis of the generic asset provided an overview of t

Join for free to read